Company: GRCE
Filing Date: 2025-03-10
Form Type: S-3
Source: 0001140361-25-007769
Chunk: 14

Company: Grace Therapeutics, Inc.
Filing Date: 2025-03-10
Form: S-3
Chunk 14
---
 securities. Additional risks and
          uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business.

<div align='center'>4</div>

#### TABLE OF CONTENTS

### USE OF PROCEEDS
The net proceeds from any disposition of our Common Stock offered hereby will be
          received by the Selling Stockholders. We will not receive any of the proceeds from any such shares of Common Stock. We will, however, receive the net proceeds of any Warrants exercised for cash. We expect to use the net proceeds received from the
          exercise of the Warrants for cash, if any, for general corporate purposes and to fund pre-commercial planning, commercial team build out and product launch if GTx-104 is approved.

<div align='center'>5</div>

TABLE OF CONTENTS

SELLING STOCKHOLDERS We have prepared this prospectus supplement to allow the Selling Stockholders to offer and sell from time to time the Shares and Warrant Shares. For additional information regarding the issuance of the Shares and the Warrants, see the section entitled “Prospectus Summary — Description of the Transaction” above. The Common Stock beneficially owned prior to the offering by the Selling Stockholders in the table below is based on information supplied to us by the Selling Stockholders, with beneficial ownership determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to the Common Stock. This information does not necessarily indicate beneficial ownership for any other purpose. The percentage of beneficial ownership after this offering is based on 13,718,106 shares of Common Stock outstanding as of March 7, 2025. The Selling Stockholders may sell some, all or none of the shares of Common Stock offered by this prospectus from time to time. We do not know how long the Selling Stockholders will hold the shares of Common Stock covered hereby before selling them and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding the sale or other disposition of any shares of Common Stock. In addition, since the date on which the Selling Stockholders provided the information, the Selling Stockholders may have sold, transferred or otherwise disposed of all or a portion of the shares of Common Stock in transactions exempt from the registration requirements of the Securities Act. Any changed information given to us by the Selling Stockholders will be set forth in prospectus supplements, post-effective amendments or in filings we make with the SEC under the Securities Exchange Act of 1934, as amended (